We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients.
- Recent EXAS Stock Price: $78.07
- Yearly Gain for EXAS stock: 63.34%
- Market Cap for EXAS stock: $14.20B
- P/E Ratio for EXAS stock: -26.992
Will EXAS's stock price go up? Is there an accurate EXAS stock forecast available?
TipRanks.com reports that Exact Sciences currently has 15 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $85.00. The target pricing ranges from a high EXAS forecast of $100.00 down to a low forecast of $70.00. Exact Sciences (EXAS)’s last closing stock price was $78.07 which would put the average price target at 8.88% upside.
In addition, TradingView issued a Buy rating for EXAS stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on EXAS stock.
Other analysts covering EXAS include:
- Daniel Arias of Stifel Nicolaus issued a Buy rating with the price target of $ 85 on 1 day ago
- Mark Massaro of BTIG issued a Buy rating with the price target of $ 90 on 1 day ago
- Puneet Souda of SVB Securities issued a Buy rating with the price target of $ 90 on 1 day ago
- Brandon Couillard of Jefferies issued a Buy rating with the price target of $ 82 on 1 day ago
If you are wondering if EXAS is a good stock to buy, here are 3rd party ratings for EXAS stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 39% (98 out of 251)
What is the sentiment on the street regarding Exact Sciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for EXAS stock: Very Bullish
- Blogger Consensus for EXAS stock: Bullish
- Media Buzz for EXAS stock: Medium
- Insider Signal for EXAS stock: ―
- Investor Sentiment for EXAS stock: Very Negative
- Hedge Fund signal for EXAS stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on EXAS stock including scouring the social networks like EXAS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for EXAS stock chart >>
Summary: Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
- Recent GH Stock Price: $27.11
- Yearly Gain for GH stock: -4.34%
- Market Cap for GH stock: $2.83B
- P/E Ratio for GH stock: -4.243
Will GH's stock price go up? Is there an accurate GH stock forecast available?
TipRanks.com reports that Guardant Health currently has 17 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $52.60. The target pricing ranges from a high GH forecast of $88.00 down to a low forecast of $28.00. Guardant Health (GH)’s last closing stock price was $27.11 which would put the average price target at 94.02% upside.
In addition, TradingView issued a Buy rating for GH stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on GH stock.
Other analysts covering GH include:
- Tejas Savant of Morgan Stanley issued a Buy rating with the price target of $ 60 on 22 hours ago
- Dan Leonard of Credit Suisse issued a Buy rating with the price target of $ 55 on 1 day ago
- Derik De Bruin of Bank of America Securities issued a Buy rating with the price target of $ 57 on 1 day ago
- Patrick B Donnelly of Citigroup issued a Hold rating with the price target of $ 28 on 1 day ago
If you are wondering if GH is a good stock to buy, here are 3rd party ratings for GH stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 39% (98 out of 251)
What is the sentiment on the street regarding Guardant Health? (Current ratings compiled by TipRanks.com)
- News Sentiment for GH stock: Very Bullish
- Blogger Consensus for GH stock: Neutral
- Media Buzz for GH stock: Low
- Insider Signal for GH stock: Positive
- Investor Sentiment for GH stock: Neutral
- Hedge Fund signal for GH stock: Negative
The stock market is extremely volatile, and you need to do your own research on GH stock including scouring the social networks like GH StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for GH stock chart >>
Summary: Mirati Therapeutics, Inc. is a clinical-stage biotech developing kinase inhibitors and KRAS inhibitors.
- Recent MRTX Stock Price: $48.12
- Yearly Gain for MRTX stock: -8.13%
- Market Cap for MRTX stock: $2.79B
- P/E Ratio for MRTX stock: -3.697
Will MRTX's stock price go up? Is there an accurate MRTX stock forecast available?
TipRanks.com reports that Mirati Therapeutics currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $64.64. The target pricing ranges from a high MRTX forecast of $90.00 down to a low forecast of $50.00. Mirati Therapeutics (MRTX)’s last closing stock price was $48.12 which would put the average price target at 34.33% upside.
In addition, TradingView issued a Buy rating for MRTX stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MRTX stock.
Other analysts covering MRTX include:
- Silvan Tuerkcan of JMP Securities issued a Buy rating with the price target of $ 61 on 22 hours ago
- Yigal Nochomovitz of Citigroup issued a Hold rating with the price target of $ 51 on 1 day ago
- Andrew Berens of SVB Securities issued a Buy rating with the price target of $ 75 on 1 day ago
- Michael Ulz of Morgan Stanley issued a Hold rating with the price target of $ 51 on 1 day ago
If you are wondering if MRTX is a good stock to buy, here are 3rd party ratings for MRTX stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Buy, Top 39% (98 out of 251)
What is the sentiment on the street regarding Mirati Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for MRTX stock: Very Bullish
- Blogger Consensus for MRTX stock: Bullish
- Media Buzz for MRTX stock: High
- Insider Signal for MRTX stock: ―
- Investor Sentiment for MRTX stock: Very Negative
- Hedge Fund signal for MRTX stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on MRTX stock including scouring the social networks like MRTX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MRTX stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
